Pembrolizumab for advanced cervical cancer: Safety and efficacy
Abstract
Introduction: Pembrolizumab is an immune checkpoint inhibitor with high specificity for binding to the programmed cell death 1 (PD-1) receptor. It has been approved by the FDA in patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express the programmed cell death ligand 1 (PD-L1).Areas covered: Clinical studies of pembrolizumab in cervical cancer were analyzed and discussed. Data were obtained by searching for English peer-reviewed articles on PubMed, clinical trials registered on clincaltrials.gov and related abstracts on the ASCO meeting library. The aim was to review the status of pembrolizumab, the published and ongoing trials, and its safety and efficacy.Expert opinion: Pembrolizumab may ultimately represent a treatment of choice for advanced cervical cancer with PD-L1 expression, both in metastatic and recurrent setting. However, it is essential to better identify and characterize patients that will benefit the most.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The FDA recently confirmed (13 October 2021) that a combination of pembrolizumab and chemotherapy drugs, with or without bevacizumab, can have therapeutic benefits for patients with recurrent metastatic cervical cancer whose tumour cells express high levels of PD-L1.
“The FDA recently confirmed (13 October 2021) that a combination of pembrolizumab and chemotherapy drugs, with or without bevacizumab, can have therapeutic benefits for patients with recurrent metastatic cervical cancer whose tumour cells express high levels of PD-L1 [39].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [39]
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444 · see citing works
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · see citing works
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · see citing works
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · see citing works
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · see citing works
Marabelle, A., Le, D. T., Ascierto, P. A., Giacomo, A. M. D., Jesus‐Acosta, A. D., Delord, J., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.02105 · Cited by 3,077 · see citing works
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,036 · see citing works
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360 · see citing works
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · see citing works
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Marth, C., Landoni, F., Mahner, S., McCormack, M. M., González-Martı́n, A., & Colombo, N. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx220 · Cited by 1,083 · see citing works
Chung, H. C., Ros, W., Delord, J., Perets, R., Italiano, A., Shapira‐Frommer, R., Manzuk, L., Piha-Paul, S. A., Xu, L., Zeigenfuss, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01265 · Cited by 1,075 · see citing works
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Formenti, S. C., & Demaria, S. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs629 · Cited by 1,058 · see citing works
Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways
Fife, B. T., & Bluestone, J. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00662.x · Cited by 1,052 · see citing works
Tewari, K. S., Sill, M. W., Penson, R. T., Huang, H. Q., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J. A., Leitão, M. M., Michael, H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31607-0 · Cited by 693 · see citing works
Howitt, B. E., Shukla, S. A., Sholl, L. M., Ritterhouse, L. L., Watkins, J. C., Rodig, S. J., Stover, E. H., Strickland, K. C., D’Andrea, A. D., Wu, C. J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2151 · Cited by 687 · see citing works
Tumor Immunotherapy Directed at PD-1
Ribas, A. (2012) · New England Journal of Medicine · doi:10.1056/nejme1205943 · Cited by 680 · see citing works
Frenel, J., Tourneau, C. L., O’Neil, B. H., Ott, P. A., Piha-Paul, S. A., Gomez‐Roca, C., van Brummelen, E. M. J., Rugo, H. S., Thomas, S., Saraf, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.5471 · Cited by 537 · see citing works
PD-1 and its ligands in T-cell immunity
Keir, M. E., Francisco, L. M., & Sharpe, A. H. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.04.012 · Cited by 432 · see citing works
DNA polymerase ɛ and δ exonuclease domain mutations in endometrial cancer
Church, D. N., Briggs, S., Palles, C., Domingo, E., Kearsey, S. J., Grimes, J. M., Gorman, M., Martin, L. M., Howarth, K. M., Hodgson, S. V., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt131 · Cited by 354 · see citing works
Monk, B. J., Sill, M. W., Burger, R. A., Gray, H. J., Buekers, T., & Roman, L. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9043 · Cited by 346 · see citing works
Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers
Mezache, L., Paniccia, B., Nyinawabera, A., & Nuovo, G. J. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.108 · Cited by 311 · see citing works
Heeren, A. M., Punt, S., Bleeker, M. C. G., Gaarenstroom, K. N., van der Velden, J., Kenter, G. G., de Gruijl, T. D., & Jordanova, E. S. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.64 · Cited by 309 · see citing works
Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
Noguchi, T., Ward, J. P., Gubin, M. M., Arthur, C. D., Lee, S. H., Hundal, J., Selby, M. J., Graziano, R. F., Mardis, E. R., Korman, A. J., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0391 · Cited by 301 · see citing works
Monk, B. J., Mas, L. A., Zarbá, J. J., Oaknin, A., Tarpin, C., Termrungruanglert, W., Alber, J. A., Ding, J., Stutts, M. W., & Pandite, L. N. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9571 · Cited by 266 · see citing works
Ribas, A., Robert, C., Hodi, F. S., Wolchok, J. D., Joshua, A. M., Hwu, W., Weber, J. S., Zarour, H. M., Kefford, R. F., Loboda, A. P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3001 · Cited by 201 · see citing works
Camouflage and sabotage: tumor escape from the immune system
Poschke, I. C., Mougiakakos, D., & Kiessling, R. W. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1012-8 · Cited by 168 · see citing works
Lheureux, S., Butler, M. O., Clarke, B. A., Cristea, M. C., Martin, L. P., Tonkin, K. S., Fleming, G. F., Tinker, A. V., Hirte, H. W., Tsoref, D., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3776 · Cited by 160 · see citing works
Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.
Verschraegen, C. F., Levy, T., Kudelka, A. P., Llerena, E., Ende, K., Freedman, R. S., Edwards, C. L., Hord, M., Steger, M., Kaplan, A. L., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.625 · Cited by 135 · see citing works
PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
Kleinovink, J. W., Marijt, K. A., Schoonderwoerd, M. J. A., van Hall, T., OSSENDORP, F. A., & Fransen, M. F. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1294299 · Cited by 133 · see citing works
Bookman, M. A., Blessing, J. A., Hanjani, P., Herzog, T. J., & Andersen, W. A. (2000) · Gynecologic Oncology · doi:10.1006/gyno.2000.5807 · Cited by 125 · see citing works
Muderspach, L. I., Blessing, J. A., Levenback, C., & Moore, J. L. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2000.6024 · Cited by 118 · see citing works
Muggia, F. M., Blessing, J. A., Method, M. W., Miller, D. S., Johnson, G. A., Lee, R. B., & Menzin, A. W. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.10.045 · Cited by 71 · see citing works
Alberts, D. S., Blessing, J. A., Landrum, L. M., Warshal, D. P., Martin, L. P., Rose, S. L., Bonebrake, A. J., & Ramondetta, L. M. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.09.008 · Cited by 67 · see citing works
Phase II Clinical Trial of Docetaxel in Refractory Squamous Cell Carcinoma of the Cervix
García, A. A., Blessing, J. A., Vaccarello, L., & Roman, L. D. (2007) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31803377c8 · Cited by 65 · see citing works
Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors
Felice, F. D., Marchetti, C., Palaia, I., Musio, D., Muzii, L., Tombolini, V., & Panici, P. B. (2015) · Journal of Immunology Research · doi:10.1155/2015/191832 · Cited by 63 · see citing works
Schilder, R. J., Blessing, J. A., & Cohn, D. E. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.09.027 · Cited by 63 · see citing works
Immune check-point in cervical cancer
Felice, F. D., Marchetti, C., Palaia, I., Ostuni, R., Muzii, L., Tombolini, V., & Panici, P. B. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.06.006 · Cited by 58 · see citing works
Marchetti, C., Fagotti, A., Tombolini, V., Scambia, G., & Felice, F. D. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101945 · Cited by 55 · see citing works
Liu, Y. L., & Zamarin, D. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0740-8 · Cited by 53 · see citing works
Lorusso, D., Ferrandina, G., Pignata, S., Ludovisi, M., Viganò, R., Scalone, S., Scollo, P., Breda, E., Pietragalla, A., & Scambia, G. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp266 · Cited by 51 · see citing works
Rose, P. G., Blessing, J. A., Lele, S., & Abulafia, O. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.11.048 · Cited by 50 · see citing works
Chen, J., Dawoodji, A., Tarlton, A., Gnjatic, S., Tajar, A., Karydis, I., Browning, J., Pratap, S., Verfaille, C., Venhaus, R. R., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29118 · Cited by 48 · see citing works
Immune check-point in endometrial cancer
Felice, F. D., Marchetti, C., Tombolini, V., & Panici, P. B. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01437-7 · Cited by 44 · see citing works
Marchetti, C., Felice, F. D., Pinto, A. D., Romito, A., Musella, A., Palaia, I., Monti, M., Tombolini, V., Muzii, L., & Panici, P. B. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2017.141 · Cited by 39 · see citing works
Delord, J., Hollebecque, A., de Boer, J. P., Grève, J. D., Machiels, J., Leidner, R. S., Ferris, R. L., Rao, S., Soumaoro, I., Cao, Z. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.6025 · Cited by 31 · see citing works
Pembrolizumab in recurrent advanced cervical squamous carcinoma.
Martínez, P., & del Campo, J. D. (2017) · Immunotherapy · doi:10.2217/imt-2016-0119 · Cited by 13 · see citing works
Activity of Pembrolizumab in Recurrent Cervical Cancer Case Series and Review of Published Data
Kranawetter, M., Röhrich, S., Müllauer, L., Obermair, H., Reinthaller, A., Grimm, C., Sturdza, A. E., Köstler, W. J., & Polterauer, S. (2018) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000001291 · Cited by 13 · see citing works
Piha-Paul, S. A., Bennouna, J., Albright, A. V., Nebozhyn, M., McClanahan, T. K., Ayers, M., Lunceford, J. K., & Ott, P. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.1536 · Cited by 12 · see citing works
Ren, Y., Lv, Q., Yue, W., Liu, B., & Zou, Z. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000620 · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Immune Checkpoint Inhibitors in Cancer Therapy
Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353 · see citing works
Nanoparticle-based immunoengineering strategies for enhancing cancer immunotherapy
Dang, B.-T. N., Kwon, T. K., Lee, S., Jeong, J., & Yook, S. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.007 · Cited by 51 · see citing works
Current landscape of personalized clinical treatments for triple-negative breast cancer
Zhang, J., Xia, Y., Zhou, X., Yu, H., Tan, Y., Du, Y., Zhang, Q., & Wu, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.977660 · Cited by 38 · see citing works
Shi, Y., Wang, A.-J., Liu, X., Dai, M., & Cai, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1193222 · Cited by 30 · see citing works
Zhang, C., Sheng, Y., Sun, X., & Wang, Y. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10113-2 · Cited by 33 · see citing works
Anticancer natural products targeting immune checkpoint protein network
Chun, K., Kim, D., Raut, P. K., & Surh, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.11.006 · Cited by 23 · see citing works
Sai, C., Qin, W., Meng, J., Gao, L., Huang, L., Zhang, Z., Wang, H., Chen, H., & Yan, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.668348 · Cited by 18 · see citing works
Peng, Y., Pan, J., Ou, F., Wang, W., Hu, H., Chen, L., Zeng, S., Zeng, K., & Yu, L. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.109983 · Cited by 15 · see citing works
Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives
Giudice, E., Mirza, M. R., & Lorusso, D. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01463-9 · Cited by 14 · see citing works
Qi, L., Li, N., Lin, A., Wang, X., & Cong, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.910486 · Cited by 14 · see citing works
Lin, Y., Huang, S., Qi, Y., Xie, L., Jiang, J., Li, H., & Chen, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1052201 · Cited by 13 · see citing works
Metal-based approaches to fight cervical cancer
Pereira, D., Alves, N. M., Sousa, Â., & Valente, J. F. A. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104073 · Cited by 11 · see citing works
Zheng, Z., Song, X., Qiu, G., Xu, S., & Cai, H. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2178081 · Cited by 9 · see citing works
Chizenga, E. P., & Abrahamse, H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050626 · Cited by 9 · see citing works
Chiliquinga, A. J., Acosta, B., Ogonaga-Borja, I., Villarruel-Melquiades, F., de la Garza, J., Gariglio, P., Ocadiz‐Delgado, R., Ramírez, A., Sánchez-Pérez, Y., García-Cuellar, C. M., et al. (2023) · Cells · doi:10.3390/cells12101376 · Cited by 6 · see citing works
A viral attack on brain tumors: the potential of oncolytic virus therapy
Mokhtarpour, K., Akbarzadehmoallemkolaei, M., & Rezaei, N. (2024) · Journal of NeuroVirology · doi:10.1007/s13365-024-01209-8 · Cited by 4 · see citing works
Liang, H., Xiang, L., Wu, H., Liu, Y., Tian, W., & Zeng, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1135626 · Cited by 3 · see citing works
Guo, L., Su, Y., Liu, X., Xie, W., Meng, S., Liu, Y., Wang, W., Lv, X., & Wang, C. (2023) · Oncology Letters · doi:10.3892/ol.2023.14000 · Cited by 3 · see citing works
Immunotherapeutics in Clinical Trials for Cervical Cancer
Yadagiri, U., Shaik, R., Kolure, R., Fatima, T., & Khan, H. (2025) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2025.0031 · Cited by 2 · see citing works
Yamada, R., Kawakami, F., Maeda, N., Nagao, S., Yamamoto, M., Motohara, T., Kondoh, E., Mikami, Y., & Komohara, Y. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156146 · Cited by 2 · see citing works
Treatment Strategies for Recurrent Cervical Cancer
翟, 静. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.13102129 · Cited by 1 · see citing works
Wu, Y., Zhang, G., Yin, P., Wen, J., Su, Y., & Zhang, X. (2024) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2024.106043 · Cited by 1 · see citing works
Gomase, V. S., Ghatule, A. P., Sharma, R., & Dhamane, S. P. (2025) · Current Cancer Therapy Reviews · doi:10.2174/0115733947375176250409173916 · Cited by 1 · see citing works
Glycolytic reprogramming and the EMT drive cervical cancer progression via the NQO1/HIF1α-SIX1 axis
Zhu, G., Piao, Z., Gao, Y., Cong, X., Wei, P., Han, A., Zhou, H., Lin, Z., & Jin, T. (2026) · iScience · doi:10.1016/j.isci.2026.117007 · Cited by 1 · see citing works
Authors, V. (2013) · Current Oncology · doi:10.3747/co.20.1906
Application of PD-1/PD-L1 Inhibitors in Gynecological Tumors
陈, 学. (2024) · World Journal of Cancer Research · doi:10.12677/wjcr.2024.141008
Kafedjiiski, K., Kurdov, R., & Belcheva, V. (2023) · Annual for Hospital Pharmacy · doi:10.14748/ahp.v9i1.9228
Research Advances in Nasal Epithelial Organoids and Challenges in Clinical Disease Applications
Xia, M., & Chengcheng, L. (2025) · Materials Lab · doi:10.54227/mlab.20250004
Identification of biomarkers associated with SUMO modification in heart failure
Chen, Z., Zhao, J., Xiao, N., Zhang, F., Zhao, S., & Yin, H. (2025) · Medicine · doi:10.1097/md.0000000000044982
Rezaei, A., Aghakhani, A., Bahreini, F., & Uversky, V. N. (2026) · International Reviews of Immunology · doi:10.1080/08830185.2026.2656636
- Authors
- De Felice, F., Giudice, E., Bolomini, G., Distefano, M. G., Scambia, G., Fagotti, A., & Marchetti, C.
- Affiliations
- Department of Radiotherapy, Policlinico Umberto I, “Sapienza„ University of Rome, Rome, Italy
- Università Cattolica del Sacro Cuore (IT)
- Agostino Gemelli University Polyclinic (IT)
- Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- Venue
- Expert Review of Anticancer Therapy
- Publisher
- Informa UK Limited
- Published
- 2020-11-26
- Volume
- 21
- Issue
- 2
- Pages
- 221-228
- ISSN
- 1473-7140 (ISSN-L)
- 1744-8328
- OpenAlex
- W3099355091
- Cited by
- 30
- References
- 50
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 4 · 2023: 11 · 2022: 4 · 2021: 3 · 2013: 1
- FWCI
- 1.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Anticancer Therapy (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- no funding
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Keywords
- pembrolizumab, advanced cervical cancer, recurrent cervical cancer, metastatic cervical cancer, immune checkpoint inhibitors, PD-1, PD-L1 expression, treatment safety, treatment efficacy, patient selection
- MeSH terms
- Immune Checkpoint Inhibitors, Uterine Cervical Neoplasms, Female, Humans, Disease Progression, B7-H1 Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
